GSK Consumer Healthcare announces availability of OTC children's Flonase Allergy Relief
During the past 20 years, the number of children suffering from allergies has doubled, and reports show that allergies now affect an estimated 40% of children nationwide. A recent survey commissioned by the makers of Children's Flonase Allergy Relief revealed that a majority of parents of young children with seasonal allergies tend to limit their children's time outdoors during allergy season. But this spring, parents can let their children play outside with confidence with the launch of Children's Flonase Allergy Relief.
Available without a prescription, Children's Flonase is an over-the-counter (OTC) nasal spray approved to offer relief of allergy symptoms including runny nose, sneezing, itchy nose, congestion, and itchy, watery eyes. Children's Flonase is a safe, non-habit forming way for children ages four and older to get relief from their nose- and eye-related allergy symptoms. Its active ingredient, fluticasone propionate, has been the No. 1 pediatrician-prescribed nasal allergy medicine for more than 5 years.
The survey of more than 1,000 parents of children (ages 4–11) with allergies provides insights into the challenges of helping to manage their children's symptoms. The results found that 67% of parents have limited their child's time outside during allergy season, and with so many treatment options, 38% of parents said they find it difficult to pick an OTC allergy medicine.
"I see a lot of parents come in whose children are suffering from seasonal or year-round allergies," said Rebecca Newman, a Chicago-area pediatrician with 25 years of practice experience and mother of two boys. "Parents often make accommodations in their children's daily activities, like limiting their time spent outdoors. What they don't realize is that keeping children in a sterile environment does not guarantee that they'll stay allergy-free, and there are products available that block allergy triggers so children can continue enjoying their favorite activities."
Children's Flonase works differently from single-ingredient antihistamines, because it blocks six allergic substances instead of just one. It reduces inflammation and relieves allergy symptoms caused by pollen, mold spores, dust mites and pet dander.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance